Prepared for Erik & Crispijn · Confidential

Account intelligence · Sample output · Agent 01 · July 2026

XXL Nutrition.
Pain, match, position, sequence.

A worked example of what the account intelligence agent produces per focus account — and what I would do with it in week one. Everything here is built from public signals only: interviews, trade press, podcasts, their own site and job posts. Pain points are therefore hypotheses to test in discovery, not confirmed facts. This is exactly how I'd want every tier-1 account documented before the first call.

Disclaimer — this case is written as if XXL Nutrition were a new logo. In reality XXL Nutrition is already a Whisk customer. I've kept the net-new angle purely as an illustration of how the agent works. The angles hold either way: for an existing account the same pain mapping makes unspoken problems visible, reopens the conversation strategically beyond the current order book, and is exactly how I would expand share of wallet with Whisk.

Account XXL Nutrition B.V.

HQ Vuurijzer 18, Deurne (NL)

Founded 2005 · founder-owned

Status Existing Whisk client · doubling candidate

Section 01

Account snapshot — the facts

Revenue

>€100M

Passed the mark in 2025, growing 25–30% YoY

Geography

NL core · BE 15–20%

Germany named the priority growth market: “big, competitive, relatively untapped” (CFO)

Channel shift

Retail 10–15% → 20–25%

In one year. Supermarkets, gyms, petrol/convenience, Hema, Jumbo, Lidl Germany

Assortment

3,500+ SKUs

Largest sports nutrition range in Benelux; own label is the core of revenue

Organisation

~120–200 people

Flat, informal, hands-on. Own B2B team with account managers and wholesale portal

Quality set-up

NutriControl testing

External lab on ingredients, nutritionals, amino profile, contaminants; Creapure® on select creatine

Ops posture

Controlled growth

CFO: “deliberately invested in scalability and efficiency” after explosive growth

Owner mindset

Simple, hands-on

René van der Zel: growth is not a goal in itself; small concrete improvements over grand plans

Two facts that shape everything below. First: they publicly credit strong supplier relationships during the creatine shortage for market-share gains — this company has learned, painfully and profitably, that supply security equals share. Second: the founder has openly discussed moving the business abroad over the Dutch business climate, and Germany is 30km from the border — so “European production close to the market” is a live strategic topic.

Section 02

Pain-point analysis — hypotheses

Six hypotheses, each built backwards from a public signal. Signal (what's observable), pain (what it likely costs them), so what (the discovery question that proves or kills it). Confidence is my read on how likely the pain is real and currently unsolved.

Pain 01 · Supply security

Confidence High

One shortage away from losing the share they just won

Signal: They publicly attribute share gains during the creatine shortage to strong supplier relationships. Creapure® on select lines = dependence on branded raw-material allocation.
Pain: Concentration risk on key actives. In a scarcity cycle, the brand with a second qualified source wins the shelf. At €100M+ with 25–30% growth, one allocation cut is a multi-million revenue event.
So what: “When creatine got tight, what did that cost you in lost weeks — and what's your dual-source position on your top five actives today?”

Pain 02 · German expansion

Confidence High

The growth market has different supply physics

Signal: Germany named the top priority by the CFO; Lidl Germany listed. Germany is Europe's largest supplement market and home turf of vertically integrated giants (TQG/ESN, >€1B).
Pain: German label compliance, German-language artwork, retailer-specific packaging specs, tighter OTIF and volume commitments — against competitors who own their factories.
So what: “For the German listings you're chasing in the next 12 months — what's the gap between the volume you could sell and the volume you can reliably supply?”

Pain 03 · Channel shift

Confidence High

An e-com supply base now serving retail buyers

Signal: Retail jumped from 10–15% to 20–25% of revenue in a single year: 4,500+ supermarket and petrol locations, 1,300+ gyms, Hema, Jumbo.
Pain: Retail runs on range-review windows, promo volume spikes, penalty-backed service levels and retailer quality audits. A supplier base optimised for webshop replenishment struggles with that rhythm.
So what: “Which of your current suppliers can pass a retailer quality audit and hold a promo peak — and which ones become the bottleneck?”

Pain 04 · Complexity

Confidence Medium

3,500 SKUs, and a deliberate reset toward control

Signal: Explosive growth followed by an explicit shift to “controlled growth”, investment in scalability and efficiency, a 10,000 m² operation.
Pain: Supplier fragmentation is an efficiency tax: more contacts, more quality files, more MOQs, more failure points per launch.
So what: “How many production partners sit behind your own-label range today — and what would it be worth to run the same range through fewer?”

Pain 05 · Format breadth

Confidence Medium

The category is moving beyond powders

Signal: Protein dairy via the Zuivelhoeve partnership, own protein and sport-water machines, foodservice and convenience listings. Gummies and liquids are the fastest-growing formats.
Pain: Every new format usually means a new specialist manufacturer, a new qualification cycle and a new MOQ — innovation speed capped by supplier onboarding speed.
So what: “When you decide to launch a gummy or a liquid, how long does it take from decision to first pallet — and where does that time actually go?”

Pain 06 · Margin & cost base

Confidence Medium

Price-led channels compress a founder-funded P&L

Signal: No investors — growth is self-funded. Expansion into discount-adjacent channels (petrol, convenience, Lidl) plus public frustration with the Dutch cost and tax climate.
Pain: Retail and convenience carry lower gross margin per unit and tie up working capital in inventory. Every point of COGS and every week of lead time is cash — with no investor cushion.
So what: “On the retail lines specifically, where does the margin land versus your webshop — and how much cash is sitting in inventory because of lead times?”

Section 03

The match — pain to Whisk capability

Only claims Whisk can actually stand behind, taken from their own public positioning. Anything marked verify I want confirmed internally before I put it in front of a customer.

Pain

Whisk capability

Proof point

Value to XXL

01 · Supply security

Own EU factory (Rijnsburg, NL) as a qualified second source on key actives

IFS Food certified, HACCP, GFSI standards; production in the Netherlands

Share protection — a qualified second source turns the next shortage from a loss into a gain

02 · German expansion

EU production close to the market + label compliance checking + distribution reach

Delivery to 220 countries; label compliance checking as a standard service (verify)

Speed to shelf — German artwork and compliance handled in the supply chain, not in their team

03 · Channel shift to retail

Retail-grade quality documentation and audit-ready production

Already producing for Holland & Barrett and Hema — retailer audits passed in practice

Audit confidence — a partner whose files already survive retail scrutiny

04 · Complexity

Full service across formulation, sourcing, production, packaging and distribution

Capsules, tablets, softgels, gummies, powders, liquids from one partner

Consolidation — fewer partners behind the same range: less admin, one relationship

05 · Format breadth

Six formats under one roof plus custom formulation and co-development

Full format range on the public product page; formulation service

Launch speed — no new supplier qualification per format

06 · Margin & cash

Cost efficiency and short lead times

Public claims: avg. 49% faster lead time, avg. 22% more affordable (verify)

COGS + working capital — margin on price, cash released on lead time

Discipline note: the 49% / 22% / 10–30% figures are Whisk's own marketing claims. Before I quote them to a buyer of René's calibre I want the measurement basis — versus which benchmark, on which product classes. An unsupported number costs more credibility than it buys.

Section 04

The value case

Rough order of magnitude to size the prize, not a proposal. Built on the public revenue figure and a 30–40% production-value assumption on the Whisk-relevant part of their range.

Addressable production walletMODEL

€25–45M

€100M+ revenue × ~80–90% nutrition products × 30–40% production value. Growing 25–30% per year on its own.

Realistic Whisk targetMODEL

2× current

Doubling today's Whisk revenue inside 12 months requires a modest share shift — the German ramp alone creates incremental volume.

The lever that lands hardestMODEL

Lead time

Faster lead times release working capital and shorten launch windows. Cheaper is copyable; faster plus certified plus local is not.

Section 05

Positioning

“You already proved that supplier strength wins share — the creatine years showed it. We're the European second source that makes that repeatable: certified, 30km-from-Germany production, six formats under one roof, and a lead time that frees up cash instead of tying it up.”

Lead with

Supply security and speed. Their own story proves they value it and will pay for it.
Concrete and small. One product, one lane, one pilot. The founder prefers one small executed thing over a grand plan.
Germany. Frame every capability against their stated number-one growth market.
Peer credibility. Founder-to-founder, operator-to-operator, no corporate theatre.
Proof over adjectives. Certificates, references, a sample, a facility visit.

Avoid

Opening on price. Cheapest is the weakest claim to a company that won share through supplier reliability.
Grand strategic narratives. “Transform your supply chain” reads as arrogance to this owner.
Unverified stat-dumping. 49% / 22% without a measurement basis gets picked apart.
Single-threading on René. Procurement, quality and product all have veto power.
Replacing their partners wholesale. Enter as the second source, earn the first.

Section 06

ICP & stakeholder map

Account ICP fit: Benelux-headquartered own-label brand, €50M+ revenue, outsourced production, multi-format range, active international expansion — a near-perfect match for Whisk's model. Buying committee below with MEDDICC roles.

Economic buyer · MEDDICC “E”

René van der Zel

CEO & founder · owner, no investors

Built the company from a garage with €5,000 borrowed; bodybuilder, hands-on, allergic to arrogance and big plans. Signs off on anything strategic.

Cares aboutSimplicity, reliability, staying independent. Supply strength as competitive weapon. Germany.

Financial gatekeeper · Metrics

Brent Van Hoof

CFO

Public voice of the “controlled growth” phase and the deliberate investment in scalability and efficiency. The natural owner of the business case.

Cares aboutCOGS per unit, inventory turns, cash tied up in lead times, cost-to-serve of the German ramp.

Likely champion · Day-to-day

Purchasing / supply chain lead

Role to be identified by name

Feels every pain in this document personally: allocation calls, MOQs, delayed pallets, quality files.

Cares aboutDual sourcing, MOQ flexibility, lead-time reliability, one contact instead of five, audit-ready documentation.

Technical buyer · Criteria

Product / category manager

Own-label range & innovation

Owns the roadmap and the launch calendar. Format breadth and co-development are their lever; supplier onboarding time is their bottleneck.

Cares aboutFormulation support, format range, sample turnaround, time from decision to first pallet.

Veto power · Risk

Quality / QA lead

Works with NutriControl externally

Can stop any supplier switch on documentation grounds alone — and is the fastest route to credibility.

Cares aboutIFS Food, HACCP, contaminant testing, batch traceability, retailer audit readiness.

Internal ally · Context

B2B / retail account managers

Own the retail & wholesale channel

They carry the retail promises to Jumbo, Hema, Lidl and the gym channel — and eat the consequences when supply slips.

Cares aboutService levels they can promise honestly, promo volume reliability, new formats to sell in.

Multi-threading rule: no €1M+ opportunity runs on a single relationship. Target coverage before any proposal: René + CFO + purchasing + product, with quality engaged early — the cheapest yes to earn and the most expensive no to discover late.

Section 07

Omnichannel entry sequence — track A: the founder

30 days, nine touches, five channels. Personalised at scale by the AI BDR stack (voice cloning, personalised video, sequencing) but written to read as one operator talking to another. The copy below is the actual draft, not a placeholder.

Day 1

LinkedIn · connect

Goal · be a person, not a pitch

René — heard you tell the creatine-shortage story and how supplier relationships turned it into share gains. Rare to hear someone credit supply instead of marketing. I work on the production side and Germany interests me. Following along.

No ask. No meeting request, no link. The only job is a recognisable, specific reason for the connection.

Day 4

LinkedIn · voice note (35s)

Goal · voice beats text for a hands-on founder

“René, Daniël from Whisk — we produce supplements from our own factory in Rijnsburg, thirty minutes from you and thirty kilometres from the German border. You said supply strength won you share when creatine got tight, and your CFO says Germany is the priority. Those two point at the same question: who produces the German volume, and how fast. Fifteen minutes for three questions. Nothing to sell yet.”

Voice-cloned and personalised per prospect via ElevenLabs — reply rates on voice run well above text in this segment.

Day 7

Email · #1

Goal · one idea, one question, no deck

Subject: second source, 30km from the German border — When creatine got tight you gained share because your suppliers held. The next scarcity cycle will pick a different active, and the brands with a qualified second source will win it again. We produce six formats from our own IFS-certified factory in Rijnsburg, and already produce for retailers who audit hard. One question: on your top five actives, do you have a second source qualified today?

If it's on the list, I'll show what qualifying us on one product looks like. One product, not a supply-chain overhaul.

Day 10

Phone · call block

Goal · catch the hands-on owner live

“René, Daniël from Whisk in Rijnsburg — I sent you a voice note about second sourcing for the German ramp. Bad moment, or do you have two minutes?”

If gatekept: ask who owns purchasing and switch that name into track B. A referral down is worth more than a voicemail up.

Day 14

Personalised video (60s)

Goal · show the plant, not slides

Walk-and-talk from the Rijnsburg floor: “This is the line your creatine or your gummy would run on. Here's the IFS file. Here's what a German-compliant label check looks like before artwork goes to print. Thirty kilometres from your growth market.”

Auto-personalised intro frame per prospect, same production footage — one asset, hundreds of variants.

Day 18

Physical · sample box

Goal · let the product argue

Sample set to Vuurijzer 18 with a handwritten card: “René — one of these is a format you don't sell yet. Curious which one you'd put in a Lidl Germany basket. — Daniël, Whisk (Rijnsburg)”

Include the lab and IFS documentation in the box, not just samples.

Day 22

Email · #2 (value)

Goal · quantify, invite

Subject: what a pilot on one SKU actually looks like — Pick one own-label SKU heading into Germany. We quote it, run the label compliance check, produce a pilot batch. You measure us on lead time, landed cost, and whether the file survives a retailer audit. If we don't beat your current lane on at least two, we've cost you an afternoon.

Worth a coffee in Deurne or a look around Rijnsburg?

Day 26

Event · invitation

Goal · relationship on neutral ground

Invite to a Whisk innovation session — new formats, category data, other own-label brands in the room — or a meet at FIBO.

Peer environment, no pitch. It makes Whisk the category insider rather than a vendor.

Day 30

Email · close the loop

Goal · leave value, keep the door open

Subject: closing this out — No reply needed. Two things before I stop emailing: one specific market observation on German own-label supplement supply, and my number if a supply lane ever gets tight. Good luck with the German ramp.

Then a 90-day nurture: quarterly value-only touches.

Section 08

Parallel tracks — running at the same time

Same account, different pain, different language, deliberately overlapping in time so the internal conversation happens without me in the room.

Track B · Purchasing / supply chain

The dual-sourcing conversation

Angle: Risk and reliability, not ambition. This person doesn't want vision, they want a second source that answers the phone in December.

“Most of my conversations start after a shortage, not before. Ours is a 30-minute qualification pack: IFS file, capacity per format, MOQ, lead times. Want it as a PDF, no call needed?”

Channels: LinkedIn + email + phone, with the quality file as the opening gift. Their currency is documentation.

Track C · Product / category manager

The innovation-speed conversation

Angle: Launch windows. Gummies and liquids are the fastest-growing formats and their onboarding time is the bottleneck.

“You already run powders. Six formats sit under one roof here, so a gummy launch doesn't need a new qualification cycle. Curious what's on your roadmap that's waiting on a supplier.”

Channels: LinkedIn + email + a physical sample of a format they don't sell. Then a co-development session invite.

Sequencing logic: track B and C start on day 5, four days behind René, so that when he asks internally “do we need this?”, two people already have the documentation in hand. Every touch, reply and call outcome is logged automatically in the CRM by the agent layer and scored against MEDDICC — so coverage gaps show up as data, not as a gut feeling.

← Back to the commercial strategy